What Brighton Collaboration does

Brighton Collaboration is a nonprofit scientific organization and program of The Task Force for Global Health's Center for Vaccine Equity, headquartered in Decatur, Georgia. Founded in 2001 as an international partnership (originally under Swiss law, reconstituted under TFGH in May 2019), it develops and disseminates standardized, peer-reviewed methods for monitoring vaccine safety and benefit-risk profiles. Its core product is a library of 76 standardized case definitions covering adverse events following immunization (AEFIs) and adverse events of special interest (AESI) across cardiac, dermatologic, neurologic, pregnancy, respiratory, and systemic categories, alongside 18 BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) templates covering viral vector, protein subunit, nucleic acid, inactivated viral, and live-attenuated vaccine platforms. Additional offerings include the SPEAC project (CEPI-funded), a Benefit-Risk Assessment Module, multilingual translations, and training programs (DSMB, CDC, vaccine courses).

The organization serves a global audience across four primary segments: vaccine manufacturers and developers, regulatory authorities and health agencies (notably WHO), clinical trial sites and research institutions, and national immunization programs in low- and middle-income countries. Brighton Collaboration is a member of the WHO Vaccine Safety Net and its BRAVATO templates have been endorsed by the WHO Global Advisory Committee on Vaccine Safety. Its standards were applied across major COVID-19 vaccine assessments (Comirnaty, Moderna, Novavax) and its case definitions underpinned the rapid 2020 response to Thrombosis with Thrombocytopenia Syndrome signals.

Brighton Collaboration operates on a grant-funded, open-access model. All case definitions, templates, and resources are provided free of charge via brightoncollaboration.org, with no commercial pricing structure. Revenue derives from institutional grants and partnerships, principally CEPI (SPEAC funding, expanded December 2022) and CDC (capacity-building across up to 50 countries), supplemented by WHO endorsement and contributions from academic and pharmaceutical partners. The organization has no external investors, no VC backing, and no disclosed revenue figures. Leadership consists of Scientific Director Dr. Robert T. Chen (ISPE 2022 awardee) and Research Director Dr. Eileen Farnon (appointed March 2024), supported by a 16-member Science Board and multiple working groups.

Name

Brighton Collaboration

Legal name

Brighton Collaboration

Website

https://brightoncollaboration.us

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Brighton Collaboration is a nonprofit scientific program of The Task Force for Global Health that develops 76 standardized case definitions and 18 BRAVATO templates for global vaccine safety monitoring, serving vaccine manufacturers, regulators (notably WHO), researchers, and national immunization programs through open-access peer-reviewed standards and CEPI/CDC-funded partnerships.

Ownership category

akta.pro rank

Product category

Vaccine Safety Science and Pharmacovigilance

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine Safety Surveillance & Adverse Event Reporting (AEFI/Pharmacovigilance) (HLAJAHAG)

Keywords

• Vaccine safety
• Case definitions
• Benefit-risk assessment
• Pharmacovigilance
• Adverse events

Headquarters

HQ city

Decatur

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Distribution channels1 record

Marketing channels6 records

Core offering

Brighton Collaboration develops and freely disseminates 76 standardized case definitions for adverse events following immunization (AEFIs) and adverse events of special interest (AESI), along with the BRAVATO suite of standardized templates for benefit-risk assessments across all major vaccine technology platforms (viral vector, protein subunit, nucleic acid, inactivated, live-attenuated). These are complemented by a Benefit-Risk Assessment Module, the CEPI-funded SPEAC project for emergency vaccine safety, multilingual translations, and training programs for vaccine safety professionals.

Product overview

Brighton Collaboration is a community promoting and improving vaccine safety through rigorous science. Its core offerings include 76 standardized Brighton Collaboration Case Definitions for evaluating adverse events following immunization (AEFIs), and the BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) suite of standardized templates for benefit-risk assessments covering viral vector, protein subunit, nucleic acid, inactivated viral, and live-attenuated vaccine platforms. These are supplemented by a Benefit-Risk Assessment Module, the SPEAC (Safety Platform for Emergency vACcines) project for emergency vaccine safety, translations in multiple languages, and training programs including DSMB training and vaccine courses. The organization operates as a program of The Task Force for Global Health.

Differentiator

Problem solved

Functional benefit

Brands

• SPEAC (Safety Platform for Emergency vACcines): A Brighton Collaboration project funded by CEPI to support the safety assessment of vaccines for epidemic preparedness.
• BRAVATO (Benefit-Risk Assessment of Vaccines by Technology)

Products and services

• Brighton Collaboration Case Definitions Standardized case definitions designed to facilitate evaluation of adverse events following immunization (AEFIs) and adverse events of special interest (AESI) for novel pathogens. Includes 76 case definitions covering cardiac, dermatologic, neurologic, pregnancy, respiratory, and systemic conditions. Used by vaccine manufacturers, regulators, and clinical trial researchers globally.
• BRAVATO Vaccine Safety Templates Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) standardized templates for collecting key information for benefit-risk assessments of new vaccine candidates across viral vector, protein subunit, nucleic acid, inactivated viral, and live-attenuated vaccine platforms. Endorsed by the WHO Global Advisory Committee on Vaccine Safety (GACVS) and used for standardized assessment of COVID-19 vaccines including Comirnaty, Moderna, and Novavax.
• Benefit-Risk Assessment Module A structured module for evaluating vaccine benefit-risk profiles, including a blank module template and case study for implementation guidance. Used by vaccine developers and regulators to conduct systematic benefit-risk assessment.
• SPEAC (Safety Platform for Emergency vACcines) A Brighton Collaboration project funded by CEPI that supports safety assessment of vaccine candidates for emergency preparedness, providing DSMB training, AESI lists, and active vaccine safety surveillance resources for vaccines targeting Lassa fever, Chikungunya, Rift Valley fever, MERS, Nipah, and COVID-19.
• Translations of Case Definitions and Templates Translated versions of Brighton Collaboration templates and case definitions, including Chinese translations of viral vector vaccine templates and Korean translations of various case definition publications, supporting global accessibility of vaccine safety standards.
• Vaccine Safety Training Programs Educational offerings including DSMB (Data Safety Monitoring Board) training, CDC training courses, and vaccine courses for building capacity in vaccine safety monitoring among clinical trial and regulatory professionals.

Quantifiable outcome

• WHO referenced Brighton Collaboration standards in a publication available through WHO IRIS for vaccine safety assessment and monitoring
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and major.

• Coalition for Epidemic Preparedness Innovations (CEPI)coreStrategic or Co-development Partner · 28 May 2019CEPI partnered with Brighton Collaboration to support safety assessment of vaccine candidates through the SPEAC (Safety Platform for Emergency vACcines) Project. CEPI funds the SPEAC project which contributes to the safety of future vaccines to prevent and respond to pandemics. CEPI expanded the partnership in December 2022 to further support safety assessment of vaccine candidates. CEPI's portfolio includes vaccines for Lassa fever, Chikungunya, Rift Valley fever, MERS, Nipah, and COVID-19.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO references Brighton Collaboration standards in its publications available through WHO IRIS. WHO Global Advisory Committee on Vaccine Safety (GACVS) has endorsed the use of BRAVATO templates. Brighton Collaboration is a member of the WHO Vaccine Safety Net. Dr. Alejandro Cravioto, Brighton Science Board member, supports the Pan-American Advisory Committee on Vaccine Safety.
• The Task Force for Global HealthcoreStrategic or Co-development PartnerBrighton Collaboration is a program of The Task Force for Global Health's Center for Vaccine Equity. The organization transitioned from a Swiss Foundation to its current status as a TFGH program in December 2019. TFGH provides administrative infrastructure including HR management through Emory University.
• Global Vaccine Data Network (GVDN)majorStrategic or Co-development PartnerGVDN is a consortium that conducts large-scale vaccine safety studies using vast datasets to detect potential safety signals. GVDN conducted the largest global vaccine safety study with 99 million people to assess neurological, blood, and heart-related conditions after COVID-19 vaccination.
• Centers for Disease Control and Prevention (CDC)majorStrategic or Co-development PartnerCDC partnered with The Task Force for Global Health to help low and middle-income countries with COVID-19 immunization programs. CDC has invested in TFGH to support COVID-19 vaccine rollout in up to 50 countries. CDC and Brighton Collaboration offer joint training courses.
• COVAX Vaccine Safety Working GroupmajorStrategic or Co-development PartnerThe COVAX Vaccine Safety Working Group (VSWG) was formed in November 2020 with representatives from Brighton Collaboration, DCVMN, IFPMA, WHO, and CEPI. The group acted as an open source of information for vaccine developers, resolved common safety challenges, and facilitated coordination within the vaccine ecosystem.
• International Network of Special Immunization Services (INSIS)majorStrategic or Co-development PartnerINSIS is a consortium of academic medical centers around the world led by University of Alberta to examine causes and risk factors of very rare adverse events linked to COVID-19 vaccines. This multimillion-dollar global initiative ensures safer vaccines are ready for future pandemics.
• University of AlbertamajorStrategic or Co-development PartnerUniversity of Alberta serves as the host institution for INSIS (International Network of Special Immunization Services), leading international vaccine safety research to study very rare adverse events associated with COVID-19 vaccines.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• ACCESS (Active Collaboration for Continuous Epidemiological Monitoring & Safety Surveillance): Multi-center U.S. consortium focused on active vaccine safety surveillance using standardized methods. Overlaps with Brighton Collaboration's mission in providing methodological frameworks for vaccine safety studies, with a U.S. focus on near-real-time signal detection.

Broad incumbents

• FDA Center for Biologics Evaluation and Research (CBER): U.S. regulator that develops vaccine safety standards and references Brighton Collaboration case definitions. Comparable as a standards and regulatory body operating in vaccine safety, though with regulatory authority rather than scientific consensus coordination.
• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI funds Brighton Collaboration's SPEAC project and is a strategic partner rather than a direct competitor. Comparable as a global vaccine R&D and pandemic preparedness organization that operates in adjacent vaccine safety infrastructure.
• The Task Force for Global Health: The parent nonprofit organization of Brighton Collaboration. Comparable as a broader global health nonprofit with multiple programs; provides administrative infrastructure and is itself a peer in the global vaccine equity and public health ecosystem.
• International Society for Pharmacoepidemiology (ISPE): The leading global professional society for pharmacoepidemiology that awarded Brighton Collaboration's Scientific Director in 2022. Comparable as a peer scientific organization in vaccine and drug safety research, with broader scope across all therapeutic areas.

Direct peers

• Global Vaccine Data Network (GVDN): Multi-country consortium that conducts large-scale vaccine safety studies using Brighton Collaboration case definitions. A direct peer as a co-implementer of global vaccine safety surveillance, with the 99M-person COVID-19 study anchoring its scientific credibility.
• Vaccine Safety Datalink (VSD): CDC-funded collaboration between the CDC and several integrated healthcare organizations that conducts active vaccine safety surveillance. A direct peer in vaccine safety monitoring, with overlapping mission in applying standardized methods to detect and evaluate adverse events.
• International Network of Special Immunization Services (INSIS): Consortium of academic medical centers led by University of Alberta to examine rare adverse events linked to COVID-19 vaccines. A direct peer and partner; comparable as a multi-country consortium focused on very rare vaccine safety signals using standardized methodology.
• Uppsala Monitoring Centre: The WHO Collaborating Centre for pharmacovigilance that operates VigiBase, the world's largest global database of adverse event reports. Directly comparable to Brighton Collaboration as a globally recognized, standards-driven pharmacovigilance organization focused on drug and vaccine safety surveillance.

Regional players

• Developing Countries Vaccine Manufacturers Network (DCVMN): Network of vaccine manufacturers from developing countries that participates in COVAX Vaccine Safety Working Group alongside Brighton Collaboration. Comparable as a partner in vaccine safety infrastructure, focused on LMIC vaccine ecosystem rather than methodology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brighton-collaboration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brighton Collaboration